September 9th 2025
The trial will evaluate the solution in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.
Rapid progress: An update on corneal endothelial cell therapy
December 8th 2023Earlier this year, Aurion’s cell therapy received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for the management of bullous keratopathy, marking the first regulatory approval in the world for an allogeneic cell therapy to manage corneal endothelial disease.
AOA 2023: Preparing to conquer keratoconus management in clinical practice
Melissa Barnett, OD, FAAO, FSLS, FBCLA, shares insights from her AOA 2023 presentation on managing keratoconus in clinical practice.
A peek into the history of the International Keratoconus Academy
Andrew Morgenstern, OD, FAAO, FNAP, gives a brief history of the International Keratoconus Academy of Eye Care Professionals.
Glaukos’ phase 3 confirmatory trial for Epioxa reaches pipeline enrollment milestone
June 5th 2023The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.
New FDA blood donor recommendations could ease restrictions on cornea donations from queer men
June 1st 2023The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities—such as transgender women or nonbinary donors—will be impacted.
ASCRS 2023: Progressive keratoconus in older patients with delayed corneal cross-linking treatment
William Trattler, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on progressive keratoconus in older patients with delayed corneal cross-linking treatment at the ASCRS annual meeting in San Diego.
ASCRS 2023: Signs of progressive keratoconus in the hair and eyes
May 6th 2023Speaking at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Marcony Santhiago, MD, points out there are subtle differences in patients with keratoconus that was progressing compared with patients whose disease was stable and healthy control subjects.
ASCRS 2023: Cenegermin 0.002%: Effective for corneal nerve regeneration in neurotrophic keratitis
May 5th 2023In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.